|
Apr 15
|
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
|
|
Apr 12
|
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
|
|
Apr 12
|
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
|
|
Apr 11
|
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
|
|
Apr 11
|
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
|
|
Apr 11
|
A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
|
|
Apr 10
|
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
|
|
Apr 10
|
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
|
|
Apr 10
|
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
|
|
Apr 9
|
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Apr 9
|
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
|
|
Apr 9
|
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
|
|
Apr 8
|
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
|
|
Apr 8
|
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
|
|
Apr 8
|
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
|
|
Apr 8
|
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
|
|
Apr 8
|
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
|
|
Apr 6
|
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
|
|
Apr 6
|
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
|
|
Apr 6
|
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
|